Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Table 2 Anti-amyloid antibodies in early AD trials: clinical efficacy, safety, and PET imaging effects

Antibody	Antibody type	Target amyloid species	Clinical efficacy	PET imaging	Safety profile
Aducanumab Biogen	IgG1 human N-terminal	Plaque, fibrils > > oligomers	ADAS-cog 27% CDR-SB 22%	Amyloid PET ~ 80% Tau PET: significant reduction	ARIA-E 35% ARIA-H 18% Headache 20%
Gantenerumab Roche	IgG1 human N-terminal and central	Plaque, fibrils, and oligomers	ADAS-cog: no effect to date, phase 3 ongoing CDR-SB: no effect to date, phase 3 ongoing	Amyloid PET ~ 75% Tau PET: not evaluated	ARIA-E 28–42% ARIA-H 15–25% Injection site erythema 13%
BAN2401 Eisai	IgG1 humanized N-terminal	Large oligomers (protofibrils) > plaque	ADAS-cog 47% CDR-SB 26%	Amyloid PET ~ 90% Tau PET: not evaluated	ARIA-E 10% ARIA-H: not reported Infusion reactions leading to discontinuations 2.5%

Abbreviations: IgG immunoglobulin G, PET positron emission tomography, ARIA-E amyloid-related imaging abnormalities with effusion or edema, ARIA-H amyloid-related imaging abnormalities with hemosiderin deposits
Data sources for target amyloid species: aducanumab [10, 11]; gantenerumab [12, 13, 20]; BAN2401 [10, 14]. Data sources for clinical and imaging data: aducanumab [11, 19]; gantenerumab [13, 20,21,22]; BAN2401 [23, 25]

ISSN: 1758-9193